AKARI Therapeutics Company
Akari is developing inhibitors of acute and chronic inflammation, specifically the complement and leukotriene systems, to treat rare and orphan diseases with unmet need.
Founded Date:
2005
Investor Type:
N/A
Employee Number:
11-50
Investment Stage:
N/A
Funding Status:
IPO
Number Of Exists:
N/A
Technology:
Scientifically-Validated Lifestyle Recommendation
Industry:
Stem Cell Exhaustion
Headquarters:
United States